Identifying microRNA/mRNA dysregulations in ovarian cancer
Open Access
- 27 March 2012
- journal article
- Published by Springer Science and Business Media LLC in BMC Research Notes
- Vol. 5 (1), 164
- https://doi.org/10.1186/1756-0500-5-164
Abstract
MicroRNAs are a class of noncoding RNA molecules that co-regulate the expression of multiple genes via mRNA transcript degradation or translation inhibition. Since they often target entire pathways, they may be better drug targets than genes or proteins. MicroRNAs are known to be dysregulated in many tumours and associated with aggressive or poor prognosis phenotypes. Since they regulate mRNA in a tissue specific manner, their functional mRNA targets are poorly understood. In previous work, we developed a method to identify direct mRNA targets of microRNA using patient matched microRNA/mRNA expression data using an anti-correlation signature. This method, applied to clear cell Renal Cell Carcinoma (ccRCC), revealed many new regulatory pathways compromised in ccRCC. In the present paper, we apply this method to identify dysregulated microRNA/mRNA mechanisms in ovarian cancer using data from The Cancer Genome Atlas (TCGA). TCGA Microarray data was normalized and samples whose class labels (tumour or normal) were ambiguous with respect to consensus ensemble K-Means clustering were removed. Significantly anti-correlated and correlated genes/microRNA differentially expressed between tumour and normal samples were identified. TargetScan was used to identify gene targets of microRNA. We identified novel microRNA/mRNA mechanisms in ovarian cancer. For example, the expression level of RAD51AP1 was found to be strongly anti-correlated with the expression of hsa-miR-140-3p, which was significantly down-regulated in the tumour samples. The anti-correlation signature was present separately in the tumour and normal samples, suggesting a direct causal dysregulation of RAD51AP1 by hsa-miR-140-3p in the ovary. Other pairs of potentially biological relevance include: hsa-miR-145/E2F3, hsa-miR-139-5p/TOP2A, and hsa-miR-133a/GCLC. We also identified sets of positively correlated microRNA/mRNA pairs that are most likely result from indirect regulatory mechanisms. Our findings identify novel microRNA/mRNA relationships that can be verified experimentally. We identify both generic microRNA/mRNA regulation mechanisms in the ovary as well as specific microRNA/mRNA controls which are turned on or off in ovarian tumours. Our results suggest that the disease process uses specific mechanisms which may be significant for their utility as early detection biomarkers or in the development of microRNA therapies in treating ovarian cancers. The positively correlated microRNA/mRNA pairs suggest the existence of novel regulatory mechanisms that proceed via intermediate states (indirect regulation) in ovarian tumorigenesis.Keywords
This publication has 36 references indexed in Scilit:
- Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell CarcinomaBMC Systems Biology, 2010
- Tangeretin Sensitizes Cisplatin-Resistant Human Ovarian Cancer Cells through Downregulation of Phosphoinositide 3-Kinase/Akt Signaling PathwayCancer Research, 2009
- Endogenous Human CaMKII Inhibitory Protein Suppresses Tumor Growth by Inducing Cell Cycle Arrest and Apoptosis through Down-regulation of the Phosphatidylinositide 3-Kinase/Akt/HDM2 PathwayJournal of Biological Chemistry, 2009
- Repertoire of microRNAs in Epithelial Ovarian Cancer as Determined by Next Generation Sequencing of Small RNA cDNA LibrariesPLOS ONE, 2009
- Comprehensive genomic characterization defines human glioblastoma genes and core pathwaysNature, 2008
- MicroRNA Expression and Identification of Putative miRNA Targets in Ovarian CancerPLOS ONE, 2008
- Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancerProceedings of the National Academy of Sciences, 2008
- Potential role of miR-9 and miR-223 in recurrent ovarian cancerMolecular Cancer, 2008
- Gene Expression Profiles Predict Early Relapse in Ovarian Cancer after Platinum-Paclitaxel ChemotherapyClinical Cancer Research, 2005
- Cell cycle genes as targets of retinoid induced ovarian tumor cell growth suppressionOncogene, 2001